"Jan. 7, 2013 -- Problems in thinking skills and depression may be more common in former National Football League players compared with other people as they age, according to a new study.
The research suggests the problems may be linke"...
Forfivo XL Side Effects Center
Medical Editor: Charles Patrick Davis, MD, PhD
Forfivo XL is an aminoketone drug indicated for the treatment of major depressive disorder. Forfivo is available as a generic termed bupropion and other names. The most common reported side effects are dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, and rash. Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness). Consumption of alcohol should be minimized or avoided.
Forfivo XL is supplied as450 mg strength tablets that should be taken once daily without food. The tablet should be swallowed whole and should not be crushed, divided, or chewed. Serious side effects include seizures, suicidal thoughts and behaviors. Patients are advised that Forfivo XL should be discontinued and not restarted if they experience a seizure while on treatment. Although Forfivo XL is not indicated for smoking cessation treatment, it contains the same active ingredient as Zyban which is approved for this use. Patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy. It is not known if Forfivo XL can harm unborn babies. Patients should notify their doctors if they are breastfeeding or plan to breastfeed. It is not known if Forfivo XL passes through breast milk. Forfivo's safety and effectiveness has not been demonstrated in the pediatric population.
Our Forfivo XL Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Forfivo XL FDA Prescribing Information: Side Effects
The following risks are discussed in greater detail in other sections of the labeling:
- Clinical worsening and suicide risk [see WARNINGS AND PRECAUTIONS]
- Neuropsychiatric symptoms and suicide risk in smoking cessation treatment [see WARNING AND PRECAUTIONS]
- Activation of mania or hypomania [see WARNINGS AND PRECAUTIONS]
- Seizures [see WARNING AND PRECAUTIONS]
- Psychosis, and other neuropsychiatric events [see WARNINGS AND PRECAUTIONS]
- Severe hypertension [see WARNINGS AND PRECAUTIONS]
- Agitation and insomnia [see WARNINGS AND PRECAUTIONS]
- Altered appetite and weight [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Commonly Observed Adverse Reactions in Controlled Clinical Trials
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse reactions from Table 5 occurring in at least 5% of patients treated with the sustained-release formulation of bupropion hydrochloride and at a rate at least twice the placebo rate are listed below for the 300- and 400-mg/day dose groups.
FORFIVO XL is bioequivalent to three 150 mg tablets of WELLBUTRIN XL®, which has been demonstrated to have similar bioavailability both to the immediate-release formulation of bupropion and to the sustained-release formulation of bupropion. The information included under this subsection and under subsections 6.2 and 6.3 is based primarily on data from controlled clinical trials with the sustained-release formulation of bupropion hydrochloride.
Adverse Reactions Leading to Discontinuation of Treatment with Bupropion Immediate Release or Bupropion Sustained Release
In placebo-controlled clinical trials, 9% and 11% of patients treated with 300 and 400 mg/day, respectively, of the sustained-release formulation of bupropion hydrochloride and 4% of patients treated with placebo discontinued treatment due to adverse reactions. The specific adverse reactions in these trials that led to discontinuation in at least 1% of patients treated with either 300 mg/day or 400 mg/day of the sustained-release formulation of bupropion hydrochloride, and at a rate at least twice the placebo rate are listed in Table 4.
Table 4: Treatment Discontinuations Due to Adverse Reactions
in Placebo-Controlled Trials for Major Depressive Disorder using Bupropion Hydrochloride
Sustained Release Formulation
|Adverse Reaction||Bupropion HCl 300 mg/day
(n = 376)
|Bupropion HCl 400 mg/day
(n = 114)
(n = 385)
In clinical trials with the immediate-release formulation of bupropion, 10% of patients and volunteers discontinued due to an adverse reaction. Reactions resulting in discontinuation, in addition to those listed above for the sustained-release formulation of bupropion hydrochloride, include vomiting, seizures, and sleep disturbances.
Adverse Reactions Occurring at an Incidence of 1% or More Among Patients Treated With Bupropion Immediate release or Bupropion Sustained Release
Table 5 enumerates adverse reactions that occurred among patients treated with 300 and 400 mg/day of the sustained-release formulation of bupropion hydrochloride and with placebo in controlled trials. Reactions that occurred in either the 300- or 400-mg/day group at an incidence of 1% or more and were more frequent than in the placebo group are included. Reported adverse reactions were classified using a COSTART-based Dictionary.
Accurate estimates of the incidence of adverse reactions associated with the use of any drug are difficult to obtain. Estimates are influenced by drug dose, detection technique, setting, physician judgments, etc. The figures cited cannot be used to predict precisely the incidence of untoward reactions in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. These incidence figures also cannot be compared with those obtained from other clinical studies involving related drug products as each group of drug trials is conducted under a different set of conditions.
Finally, it is important to emphasize that the tabulation does not reflect the relative severity and/or clinical importance of the reactions. A better perspective on the serious adverse reactions associated with the use of bupropion is provided in the WARNINGS AND PRECAUTIONS.
Table 5: Adverse Reactions in Placebo-Controlled Trials*
for Major Depressive Disorder
|Body System/ Adverse Reaction||Bupropion HCl 300 mg/day
(n = 376)
|Bupropion HCl 400 mg/day
(n = 114)
(n = 385)
|Central nervous system stimulation||2%||1%||1%|
|Blurred vision or diplopia||3%||2%||2%|
|Urinary tract infection||1%||0%||-|
|* Adverse reactions that occurred in at least
1% of patients treated with either 300 or 400 mg/day of the sustained-release
formulation of bupropion hydrochloride, but equally or more frequently
in the placebo group, were: abnormal dreams, accidental injury, acne,
appetite increased, back pain, bronchitis, dysmenorrhea, dyspepsia, flatulence,
flu syndrome, hypertension, neck pain, respiratory disorder, rhinitis,
and tooth disorder.
† Incidence based on the number of female patients.
- Hyphen denotes adverse reactions occurring in greater than 0 but less than 0.5% of patients.
Additional reactions to those listed in Table 5 that occurred at an incidence of at least 1% in controlled clinical trials of the immediate-release formulation of bupropion hydrochloride (300 to 600 mg/day) and that were numerically more frequent than placebo were: cardiac arrhythmias (5% vs. 4%), hypertension (4% vs. 2%), hypotension (3% vs. 2%), tachycardia (11% vs. 9%), appetite increase (4% vs. 2%), dyspepsia (3% vs. 2%), menstrual complaints (5% vs. 1%), akathisia (2% vs. 1%), impaired sleep quality (4% vs. 2%), sensory disturbance (4% vs. 3%), confusion (8% vs. 5%), decreased libido (3% vs. 2%), hostility (6% vs. 4%), auditory disturbance (5% vs. 3%), and gustatory disturbance (3% vs. 1%).
Other adverse reactions occurring < 1% in clinical trials
Chills, facial edema, postural hypotension, stroke, syncope, bruxism, gastric reflux, gingivitis, glossitis, increased salivation, mouth ulcers, stomatitis, edema of tongue, ecchymosis, edema, abnormal coordination, decreased libido, depersonalization, emotional lability, hyperkinesia, hypertonia, hypesthesia, ataxia, and derealization, bronchospasm, accommodation abnormality, dry eye, impotence, and prostate disorder.
The following adverse reactions have been identified during post-approval use of Bupropion hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Only those adverse reactions not previously listed for bupropion are included. The extent to which these reactions may be associated with FORFIVO XL is unknown.
Metabolic and Nutritional-glycosuria.
Musculoskeletal-muscle rigidity/fever/rhabdomyolysis and muscle weakness.
Nervous System-abnormal electroencephalogram (EEG), aggression, akinesia, aphasia, coma, delirium,dysarthria, dyskinesia, dystonia, extrapyramidal syndrome, hypokinesia, increased libido, neuralgia, neuropathy, and unmasking tardive dyskinesia.
Read the entire FDA prescribing information for Forfivo XL (Bupropion Hydrochloride) »
Additional Forfivo XL Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.